Nektar Therapeutics (NKTR) Holdings Raised by Alps Advisors Inc.

Alps Advisors Inc. raised its stake in shares of Nektar Therapeutics (NASDAQ:NKTR) by 9.9% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,958 shares of the biopharmaceutical company’s stock after acquiring an additional 13,915 shares during the period. Alps Advisors Inc. owned approximately 0.10% of Nektar Therapeutics worth $3,695,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of NKTR. Teachers Advisors LLC boosted its stake in shares of Nektar Therapeutics by 103.8% in the first quarter. Teachers Advisors LLC now owns 663,324 shares of the biopharmaceutical company’s stock valued at $15,568,000 after purchasing an additional 337,868 shares during the period. Schwab Charles Investment Management Inc. boosted its stake in shares of Nektar Therapeutics by 9.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 633,597 shares of the biopharmaceutical company’s stock valued at $14,871,000 after purchasing an additional 56,784 shares during the period. Bank of America Corp DE boosted its stake in shares of Nektar Therapeutics by 100.0% in the first quarter. Bank of America Corp DE now owns 276,642 shares of the biopharmaceutical company’s stock valued at $6,493,000 after purchasing an additional 138,330 shares during the period. HighTower Advisors LLC boosted its stake in shares of Nektar Therapeutics by 10.4% in the first quarter. HighTower Advisors LLC now owns 16,725 shares of the biopharmaceutical company’s stock valued at $391,000 after purchasing an additional 1,569 shares during the period. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Nektar Therapeutics by 34.0% in the first quarter. Goldman Sachs Group Inc. now owns 643,437 shares of the biopharmaceutical company’s stock valued at $15,101,000 after purchasing an additional 163,398 shares during the period. 95.11% of the stock is owned by institutional investors and hedge funds.

Nektar Therapeutics (NASDAQ:NKTR) traded up $0.76 during mid-day trading on Friday, reaching $32.50. 3,070,400 shares of the company’s stock were exchanged, compared to its average volume of 1,616,181. The company has a debt-to-equity ratio of 2.91, a quick ratio of 3.82 and a current ratio of 4.14. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $33.67.

Nektar Therapeutics (NASDAQ:NKTR) last released its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, topping analysts’ consensus estimates of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The company had revenue of $152.90 million for the quarter, compared to analysts’ expectations of $126.50 million. During the same quarter last year, the company earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 321.2% on a year-over-year basis. analysts predict that Nektar Therapeutics will post -0.78 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/nektar-therapeutics-nktr-holdings-raised-by-alps-advisors-inc.html.

Several research analysts have recently commented on the stock. Canaccord Genuity assumed coverage on shares of Nektar Therapeutics in a research note on Thursday. They issued a “buy” rating and a $35.00 price objective for the company. Mizuho reissued a “buy” rating and issued a $30.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday. Jefferies Group LLC reissued a “buy” rating and issued a $35.00 price objective on shares of Nektar Therapeutics in a research note on Wednesday. Cowen and Company assumed coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 7th. They issued an “outperform” rating for the company. Finally, ValuEngine raised shares of Nektar Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and eleven have assigned a buy rating to the company. Nektar Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $28.64.

In other Nektar Therapeutics news, SVP Stephen K. Doberstein sold 1,701 shares of the firm’s stock in a transaction that occurred on Wednesday, August 16th. The shares were sold at an average price of $19.32, for a total transaction of $32,863.32. Following the sale, the senior vice president now owns 31,102 shares of the company’s stock, valued at $600,890.64. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Stephen K. Doberstein sold 396,323 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was sold at an average price of $29.00, for a total transaction of $11,493,367.00. Following the sale, the senior vice president now directly owns 52,016 shares in the company, valued at approximately $1,508,464. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,024,757 shares of company stock worth $25,974,361. 6.10% of the stock is owned by corporate insiders.

Nektar Therapeutics Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Want to see what other hedge funds are holding NKTR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nektar Therapeutics (NASDAQ:NKTR).

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply